299 related articles for article (PubMed ID: 14739526)
1. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
2. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
3. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
5. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
6. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.
Maheshwari HG; Prezant TR; Herman-Bonert V; Shahinian H; Kovacs K; Melmed S
J Clin Endocrinol Metab; 2000 Sep; 85(9):3409-16. PubMed ID: 10999842
[TBL] [Abstract][Full Text] [Related]
7. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
8. Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome.
Dötsch J; Kiess W; Hänze J; Repp R; Lüdecke D; Blum WF; Rascher W
J Clin Endocrinol Metab; 1996 Nov; 81(11):3839-42. PubMed ID: 8923825
[No Abstract] [Full Text] [Related]
9. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
10. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
11. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
12. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
[TBL] [Abstract][Full Text] [Related]
14. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
15. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
Tajima T; Tsubaki J; Ishizu K; Jo W; Ishi N; Fujieda K
Endocr J; 2008 Jul; 55(3):595-9. PubMed ID: 18445999
[TBL] [Abstract][Full Text] [Related]
16. Gigantism with pituitary macroadenoma: an unusual variant of McCune-Albright syndrome.
Queirolo S; Gallarotti F; Capuano E; Garrè ML; Spaziante R; Di Battista E
J Pediatr Endocrinol Metab; 2009 Feb; 22(2):177-9. PubMed ID: 19449675
[No Abstract] [Full Text] [Related]
17. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation.
Zimmerman D; Young WF; Ebersold MJ; Scheithauer BW; Kovacs K; Horvath E; Whitaker MD; Eberhardt NL; Downs TR; Frohman LA
J Clin Endocrinol Metab; 1993 Jan; 76(1):216-22. PubMed ID: 8421089
[TBL] [Abstract][Full Text] [Related]
18. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
19. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
20. [Acromegaly associated with McCune-Albright syndrome].
Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]